Could a kidney cell injection slow Diabetes-Related kidney failure?

NCT ID NCT05018416

Completed Disease control Sponsor: Prokidney Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental cell therapy called REACT (rilparencel) in 53 adults with type 1 or 2 diabetes and chronic kidney disease. The therapy involves injecting a person's own kidney cells into their kidneys to see if it can slow the loss of kidney function. The goal is to improve safety and delay the need for dialysis or transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome type 1 diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASES TYPE 1 DIABETES MELLITUS TYPE 2 DIABETES MELLITUS

Contacts and locations

Show contact details

Locations

Boise Kidney and Hypertension Institute - Frenova

Nampa, Idaho, 83687, United States
Kidney Associates of Colorado, P.C. - Frenova

Denver, Colorado, 80210-5073, United States
Nephrology Associates

Newark, Delaware, 19713, United States
Nephrology and Hypertension Associates Ltd - Frenova

Tupelo, Mississippi, 38801-6560, United States
Paragon Health, PC d/b/a Nephrology Center, PC - Frenova

Kalamazoo, Michigan, 49007-3889, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.